Fosun Pharma's new RMB 3.5 billion R&D base and collaboration with Shanghai Institute of Materia Medica

Fosun Pharma (see the November 1, 2012 CHBP) is in the news again after  floating shares on the Hong Kong stock exchange in October. This public company has developed a reputation as  being a private equity firm in the health care industry. This is not a groundless claim, as Fosun makes a large numb...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email Thank you!

Related Research

Sinopec announces plans to become China's largest hydrogen energy company in response to China's 14th Five-Year Plan

News Commentary | March 18, 2021

One of Lux's top predictions for 2021 was that China would triple global green hydrogen capacity by 2025. While it remains to be seen where Sinopec plans to fit in China's hydrogen economy, it will start by building 1,000 hydrogen fueling stations by 2025. Lofty claims are common from China, ... To read more, click here.

Singaporean precision medicine startup Hummingbird Bioscience nets $125 million in Series C funding led by Novo Holdings

News Commentary | May 24, 2021

This will further expand Hummingbird's proprietary Rational Antibody Discovery (RAD) platform for novel therapeutic monoclonal antibodies. The market for therapeutic antibodies is rapidly growing, as new drugs have been approved for treating various human diseases, including many cancers and ... Not part of subscription

Insurers decline to cover Biogen's new Alzheimer's disease (AD) drug as the fallout continues from the FDA's controversial approval

News Commentary | July 19, 2021

Biogen's AD drug, Aduhelm, continues to stir controversy, as several private insurers have decided not to cover the high costs of the medication. This includes some affiliates of Blue Cross Blue Shield and even the CMS, despite the FDA's accelerated approval. With pharmaceuticals like Roche and Eli ... Not part of subscription